Lasmiditan
Reyvow
NADAC/unit
$88.7339
No Shortage
vs. brand Reyvow: Generic saves up to -787% per unit
Active Shortages
2025-11-03 A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026., Eli Lilly and Co.
2025-11-03 A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026., Eli Lilly and Co.
2025-11-03 A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026., Eli Lilly and Co.
2025-11-03 A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026., Eli Lilly and Co.
2025-11-03 A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026., Eli Lilly and Co.
Generic Manufacturers
ELI LILLY AND CO
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.